摘要:
Purine derivatives of the formula ##STR1## wherein R is C.sub.1 -C.sub.6 alkyl and R.sub.1 is ##STR2## and their pharmaceutically acceptable acid addition salts are non-adrenergic bronchodilators.
摘要:
Adenine derivatives with 2-alkylthio and 9-(2-cyclohexenyl or cyclohexyl) substituents having non-adrenergic bronchodilating properties and use in the treatment or prophylaxis of broncho-constriction in mammals are disclosed.
摘要:
Purine derivatives of the formula ##STR1## wherein R is C.sub.1 -C.sub.6 alkyl and R.sub.1 is ##STR2## OR ##STR3## AND THEIR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS ARE NON-ADRENERGIC BRONCHODILATORS.
摘要:
New orally active bronchodilating 6-amino-purine derivatives substituted in the two position with alkylamino or cyclohexylamino and in the nine position with 2-cyclohexenyl or cyclohexyl are disclosed.
摘要:
New 2-substituted-6-amino-9-tetrahydropyran-2-yl purine derivatives are disclosed. They are orally active bronchodilators with relatively little cardiovascular side effects. A representative and preferred embodiment of this invention is 2-n-propoxy-9-(tetrahydropyran-2-yl)-9H-adenine.
摘要:
The present invention concerns neutral sugar derivatives of pradimicins, their use as antifungal agents, methods for their preparation, and intermediates for their synthesis.
摘要:
The present invention concerns neutral sugar derivatives of pradimicins, their use as antifungal agents, methods for their preparation, and intermediates for their synthesis.
摘要:
Disclosed herein is a process for producing a (2S,5S)-2,5-diamino-1,6-diphenyl-3-hexanone derivative represented by the formula (1): ##STR1## wherein R.sup.1 means a lower alkylcarbonyl group, a halogen-substituted lower alkylcarbonyl group, an arylcarbonyl group or a lower alkoxycarbonyl group, and R.sup.2 and R.sup.3 are identical with or different from each other and denote individually an aryl group or an alkoxy-substituted aryl group, which comprises subjecting a (2S)-2,5-diamino-1,6-diphenyl-4-hexen-3-one derivative represented by the formula (2): ##STR2## wherein R.sup.1, R.sup.2 and R.sup.3 have the same meaning as defined above, to a hydrogenation reaction in the presence of a transition metal-containing catalyst.